收费全文 | 40213篇 |
免费 | 2220篇 |
国内免费 | 119篇 |
耳鼻咽喉 | 469篇 |
儿科学 | 2387篇 |
妇产科学 | 757篇 |
基础医学 | 4989篇 |
口腔科学 | 1039篇 |
临床医学 | 2858篇 |
内科学 | 8165篇 |
皮肤病学 | 990篇 |
神经病学 | 2262篇 |
特种医学 | 979篇 |
外科学 | 5637篇 |
综合类 | 1401篇 |
一般理论 | 16篇 |
预防医学 | 2290篇 |
眼科学 | 1657篇 |
药学 | 3812篇 |
中国医学 | 298篇 |
肿瘤学 | 2546篇 |
2023年 | 268篇 |
2022年 | 729篇 |
2021年 | 1313篇 |
2020年 | 713篇 |
2019年 | 981篇 |
2018年 | 1177篇 |
2017年 | 846篇 |
2016年 | 1087篇 |
2015年 | 1149篇 |
2014年 | 1568篇 |
2013年 | 2018篇 |
2012年 | 2821篇 |
2011年 | 2872篇 |
2010年 | 1603篇 |
2009年 | 1430篇 |
2008年 | 2040篇 |
2007年 | 2020篇 |
2006年 | 1980篇 |
2005年 | 1631篇 |
2004年 | 1608篇 |
2003年 | 1349篇 |
2002年 | 1151篇 |
2001年 | 843篇 |
2000年 | 879篇 |
1999年 | 758篇 |
1998年 | 338篇 |
1997年 | 235篇 |
1996年 | 237篇 |
1995年 | 230篇 |
1994年 | 190篇 |
1993年 | 162篇 |
1992年 | 506篇 |
1991年 | 413篇 |
1990年 | 435篇 |
1989年 | 401篇 |
1988年 | 362篇 |
1987年 | 363篇 |
1986年 | 353篇 |
1985年 | 328篇 |
1984年 | 265篇 |
1983年 | 221篇 |
1979年 | 235篇 |
1978年 | 157篇 |
1977年 | 184篇 |
1976年 | 144篇 |
1975年 | 174篇 |
1974年 | 182篇 |
1973年 | 184篇 |
1972年 | 173篇 |
1971年 | 161篇 |
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献Area covered: The authors discuss, herein, the need for developing radiation countermeasure agents for various sub-syndromes of acute radiation syndromes (ARS) following TBDD and PBDD approaches. With time and continuous advances in radiation countermeasure drug development research, the expectation is to have multiple radiation countermeasure agents for each sub-syndrome made available to radiation exposed victims.
Expert opinion: The majority of the countermeasures currently being developed for ARS employ the PBDD approach, while the TBDD approach is clearly under-utilized. In the future, an improved drug development strategy might be a ‘hybrid’ strategy that is more reliant on TBDD for the initial drug discovery via large-scale screening of potential candidate agents, while utilizing PBDD for secondary screening of those candidates, followed by tertiary analytics phase in order to pinpoint efficacious candidates that target the specific sub-syndromes of ARS. 相似文献